On September 15, 2016, Rochelle Hanley, M.D., F.A.C.P., the Chief Medical Officer of Viking Therapeutics, Inc., informed the company that she will be retiring and therefore resigning from the company, effective September 30, 2016. Dr. Hanley served as the company's Chief Medical Officer since April 2013. Her retirement and associated resignation were not due to any disagreement with the Company and are in accordance with previously defined milestones and a general timeline set out at the time she joined the Company.